Eli Lilly Weight-Loss Drug Outperforms Zepbound

Eli Lilly reported that its experimental combination weight-loss drug EloraTZP outperformed Zepbound in a mid-stage trial. Patients achieved significant weight loss, though discontinuation rates rose due to gastrointestinal side effects.

Xurve View
Insights:
The Eli Lilly logo is displayed at the Clinical Trials on Alzheimer’s Disease conference in San Diego, California, U.S., December 3, 2025. REUTERS/Deena Beasley

ELI LILLY & CO said on Wednesday its experimental combination weight-loss drug EloraTZP outperformed Zepbound, driving an average weight reduction of 23.3% over 48 weeks in patients with diabetes. The mid-stage trial results intensify competition with NOVO NORDISK A/S-B in the global obesity market. That compared with 14.8% for patients on the highest dose of Zepbound in the same trial.